Infliximab vs rituximab
Severe AEs · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes any severe AEs compared with rituximab (very low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 1.78 [0.2, 16.1]Studies not reportedVery low